How India Exports Immunoglobulin to the World

Immunoglobulin products are classified as biologics by the U.S. Food and Drug Administration (FDA) and are regulated under the Biologics License Application (BLA) pathway, rather than the Abbreviated New Drug Application (ANDA) process used for generic drugs. Consequently, there are no approved ANDAs for immunoglobulin products listed in the FDA's Orange Book. The FDA maintains a list of approved immunoglobulin products, including their manufacturers and indications, on its website.

Importantly, the FDA has issued Import Alert 57-11, titled "Detention Without Physical Examination of Unlicensed Immune Globulin Intravenous (Human)," effective as of October 30, 2024. This alert mandates that foreign-manufactured, unlicensed versions of intravenous immunoglobulin (IGIV) are subject to detention without physical examination unless they possess a valid U.S. license or an accepted Investigational New Drug (IND) application. This underscores the necessity for Indian exporters to ensure compliance with FDA licensing requirements to facilitate market entry into the United States.

In the European Union (EU) and the United Kingdom (UK), immunoglobulin products require marketing authorization from the European Medicines Agency (EMA) or the UK's Medicines and Healthcare products Regulatory Agency (MHRA), respectively. Manufacturers must adhere to Good Manufacturing Practice (GMP) standards as outlined in EU Directive 2003/94/EC. Notably, the EMA revised the European Pharmacopoeia monograph 0338 on human normal immunoglobulin, effective January 1, 2013, to address thromboembolic events associated with certain immunoglobulin preparations. This revision necessitates that manufacturers implement steps to remove thrombosis-generating agents during production. Compliance with these updated standards is essential for market approval within the EU and UK.

Immunoglobulin is included in the World Health Organization's (WHO) Model List of Essential Medicines, underscoring its critical role in healthcare. Manufacturers are expected to comply with international pharmacopoeia standards, including those set forth in the United States Pharmacopeia (USP), British Pharmacopoeia (BP), European Pharmacopoeia (EP), and Indian Pharmacopoeia (IP). Adherence to these standards ensures product quality and facilitates acceptance in global markets.

In India, immunoglobulin products are classified under Schedule H of the Drugs and Cosmetics Rules, 1945, indicating that they are prescription-only medicines. The National Pharmaceutical Pricing Authority (NPPA) regulates the pricing of essential medicines; however, as of March 2026, there is no specific ceiling price listed for immunoglobulin products. For export purposes, Indian manufacturers must obtain a No Objection Certificate (NOC) from the Directorate General of Foreign Trade (DGFT), ensuring compliance with national regulations and facilitating international trade.

The patent landscape for immunoglobulin products is complex, with various patents covering manufacturing processes, formulations, and therapeutic uses. While some patents may have expired, allowing for increased generic competition, others remain in force, potentially limiting market entry for certain products. Manufacturers must conduct thorough patent analyses to navigate potential intellectual property challenges effectively.

In October 2024, the FDA issued Import Alert 57-11, emphasizing the need for foreign manufacturers to obtain proper licensing for immunoglobulin products intended for the U.S. market. This development highlights the importance of regulatory compliance for Indian exporters aiming to access the U.S. market.

Additionally, the EMA's revision of the European Pharmacopoeia monograph 0338, effective January 1, 2013, continues to influence manufacturing practices. Manufacturers are required to implement steps to remove thrombosis-generating agents during production, ensuring product safety and compliance with EU standards.

These regulatory updates underscore the dynamic nature of the immunoglobulin market and the necessity for manufacturers to stay informed and compliant with evolving standards to maintain market access and competitiveness.

India's pharmaceutical industry, often referred to as the "pharmacy of the world," heavily relies on imports for Active Pharmaceutical Ingredients (APIs) and Key Starting Materials (KSMs). Approximately 70% of APIs and KSMs are sourced from China, underscoring a significant supply chain vulnerability. This dependency is particularly concerning for immunoglobulin production, as any disruption in the supply of these critical raw materials can impede manufacturing processes.

Recent geopolitical tensions and environmental regulations have led to the shutdown of several Chinese chemical manufacturing units, causing supply uncertainties and price volatility in APIs. Such disruptions highlight the fragility of the supply chain and the urgent need for India to bolster its domestic production capabilities to mitigate risks associated with external dependencies.

Our proprietary trade data indicates a high supplier concentration in India's immunoglobulin export market. The top five exporters account for 75.8% of total exports, with RELIANCE LIFE SCIENCES PRIVATE LIMITED alone holding a 47.0% share. This concentration poses a significant single-source risk; any operational or quality issues within these key suppliers could disrupt the entire supply chain.

To address such vulnerabilities, the Indian government has implemented the Production Linked Incentive (PLI) scheme aimed at enhancing domestic API and KSM production. In October 2024, two greenfield plants were inaugurated under this scheme to manufacture critical molecules like Penicillin G and Clavulanic Acid, marking a step towards reducing import dependence. However, the effectiveness of these initiatives in diversifying the supplier base for immunoglobulin remains to be seen.

The global supply chain for immunoglobulin is susceptible to geopolitical tensions and shipping disruptions. In February 2026, the U.S. and Israel initiated Operation Epic Fury against Iran, leading to the closure of the Strait of Hormuz—a critical chokepoint through which approximately 20% of global oil passes. This closure has resulted in increased shipping costs and extended transit times, impacting the timely delivery of pharmaceutical products.

Additionally, the Red Sea and Bab al-Mandab Strait have experienced disruptions due to attacks by Iran-backed Houthi forces, further complicating shipping routes. These geopolitical events have led to rerouting of shipments around the Cape of Good Hope, adding significant delays and costs to the supply chain. Such disruptions underscore the need for robust risk mitigation strategies to ensure the uninterrupted supply of immunoglobulin.

• Diversify Supplier Base: Encourage the development of multiple domestic suppliers for immunoglobulin to reduce reliance on a few key players.

• Enhance Domestic API Production: Accelerate initiatives under the PLI scheme to boost local manufacturing of critical APIs and KSMs, thereby decreasing dependence on imports.

• Strengthen Supply Chain Monitoring: Implement advanced tracking systems to monitor geopolitical developments and shipping routes, enabling proactive responses to potential disruptions.

• Develop Alternative Shipping Routes: Establish and maintain alternative logistics pathways to circumvent geopolitical hotspots, ensuring consistent delivery schedules.

• Engage in International Collaboration: Foster partnerships with international regulatory bodies and organizations to share information and resources, enhancing global supply chain resilience.

RISK_LEVEL: HIGH